People: Solazyme Inc (SZYM.O)

SZYM.O on Nasdaq

2.46USD
4 Mar 2015
Change (% chg)

-- (--)
Prev Close
$2.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,086,028
52-wk High
$15.00
52-wk Low
$2.00

Search Stocks

Summary

Name Age Since Current Position

Jerry Fiddler

62 2004 Independent Chairman of the Board

Jonathan Wolfson

43 2010 Chief Executive Officer, Director

Tyler Painter

42 2014 Chief Financial Officer, Chief Operating Officer

Peter Licari

50 2012 Chief Technology Officer

Paul Quinlan

51 2010 General Counsel, Corporate Secretary

James Craigie

60 2013 Director

Peter Kovacs

72 2013 Director

Gary Pfeiffer

64 2014 Director

Michael Arbige

60 2005 Independent Director

Ian Clark

53 2011 Independent Director

Biographies

Name Description

Jerry Fiddler

Mr. Jerry L. Fiddler is Independent Chairman of the Board of Solazyme Inc. From 1981 to 2009 Mr. Fiddler was, at various times, the founder, Chief Executive Officer, Chairman and/or director of Wind River Systems, Inc., a publicly held software company, until it was acquired by Intel Corporation, a semiconductor company. Mr. Fiddler is the principal/CEO of Zygote Ventures, LLC, and an adjunct professor at University of California, Berkeley. He serves on a number of private company and non-profit boards. Mr. Fiddler obtained an M.S. from the University of Illinois.

Jonathan Wolfson

Mr. Jonathan S. Wolfson is Chief Executive Officer and Director of Solazyme Inc. He is a co-founder. He was our President and Chief Operating Officer from 2003 until 2008 when he became Chief Executive Officer. Prior to founding Solazyme, Mr. Wolfson held a variety of positions in finance, business and law, most recently that of Vice President of Finance and Business Development for 7thOnline, Inc., a supply chain software company. Immediately prior to that, Mr. Wolfson was co-founder and Chief Operating Officer of InvestorTree, Inc., a financial services software company. Mr. Wolfson obtained a law degree from New York University (NYU) School of Law and an M.B.A. from NYU Stern School of Business.

Tyler Painter

Mr. Tyler W. Painter is Chief Financial Officer, Chief Operating Officer of Solazyme Inc. Prior to joining us, Mr. Painter served as interim Corporate Controller for PMC-Sierra (PMCS), a provider of broadband communications and internet infrastructure semiconductor solutions, from May 2007 through October 2007. From 2001 to 2007, Mr. Painter served as Vice President of Finance and Investor Relations and Corporate Treasurer for Wind River Systems, Inc., a software company. Prior to joining Wind River Systems, Inc., Mr. Painter held a variety of positions in finance at CarsDirect, Inc., an online automobile sales company, and at Gap, Inc., a retail clothing company. Mr. Painter obtained a B.S. in Business Administration/Finance from California Polytechnic State University, San Luis Obispo.

Peter Licari

Dr. Peter J. Licari, Ph.D., is Chief Technology Officer of Solazyme Inc.From 2010 to 2012, he served as our Executive Vice President, Research and Development. He served as our Senior Vice President, Research and Development from 2008 until 2010. From 1998 to 2008, Dr. Licari held various positions at Kosan Biosciences, Inc., a biopharmaceutical company. In his last position at Kosan Biosciences, Inc. he served as Senior Vice President, Manufacturing and Operations responsible for the process development and manufacturing of Kosan’s clinical compounds. From 1993 to 1996, Dr. Licari served as the Director of Vaccine Manufacturing and Development at Massachusetts Biologic Laboratories, a part of the University of Massachusetts, an academic institution. Prior to joining Massachusetts Biologic Laboratories, Dr. Licari had a variety of research positions at BASF Bioresearch Corporation, a biopharmaceutical company, and Merck & Co., Inc., a pharmaceutical company. Dr. Licari obtained his Ph.D. in Chemical Engineering from the California Institute of Technology and obtained a M.B.A. from Pepperdine University.

Paul Quinlan

Mr. Paul T. Quinlan is General Counsel and Corporate Secretary of Solazyme Inc. He has served as our General Counsel since May 2010 and as our Corporate Secretary since June 2010. From 2005 to 2010 Mr. Quinlan was General Counsel at Metabolex, Inc., a biopharmaceutical company. In this position, he was responsible for overseeing the legal affairs of Metabolex, Inc. From 2000 to 2005, Mr. Quinlan held various positions in the legal department at Maxygen, Inc., a biopharmaceutical company, most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Inc., Mr. Quinlan was an associate at Cooley LLP, a law firm, and Cravath, Swaine & Moore LLP, a law firm. Mr. Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto.

James Craigie

Mr. James R. Craigie has been appointed as Director of Solazyme, Inc., with effect from September 4, 2013. Mr. Craigie joins other board members, Ian Clark, CEO of Genentech; Ann Mather former CFO of Pixar and current board member of Google, MGM Holdings Inc., and Netflix; Peter Kovacs, former President and CEO of NutraSweet Kelco; Michael Arbige, EVP Technology of DuPont Genencor Science; and Chairman Jerry Fiddler, former CEO and founder of Wind River Systems; and Jonathan Wolfson, Solazyme CEO.

Peter Kovacs

Mr. Peter Kovacs is no longer Director of Solazyme, Inc., effective May, 2015. Mr. Kovacs has been a consultant, providing business consulting services, to a variety of companies since 1997. He has been a consultant to us since 2007. From 1994 until his retirement in 1997, Mr. Kovacs served as President and CEO of the NutraSweet Kelco Company, a nutritional and specialty chemicals company. From 1993 to 1994 he was President and CEO of the Kelco Company, a specialty chemicals company. Mr. Kovacs was employed by Kelco in various capacities from 1967, through his appointment as President and CEO in 1993, until Kelco’s acquisition by Monsanto in 1994. Mr. Kovacs obtained a B.S. in chemistry from San Diego State University.

Gary Pfeiffer

Mr. Gary M. Pfeiffer is Director of the Company. Mr. Pfeiffer retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company (DuPont), a large, multinational company with science-based products, materials and services. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer is a director of Quest Diagnostics Incorporated, a provider of clinical laboratory services and diagnostic testing to the healthcare industry, and Internap Network Services Corporation, an information technology infrastructure services company, and served as a director of The Talbots, Inc., a retailer of women’s apparel, from 2005 to 2012. He is the non-executive Chair of the Board of Directors of Christiana Care Health System, a not-for-profit regional hospital system located in Delaware. Mr. Pfeiffer holds a B.A. and an M.B.A. from the College of William and Mary in Virginia. Mr. Pfeiffer will receive director compensation consistent with the Company’s current compensation arrangement for non-employee members of the Board and has entered into the Company’s standard form of indemnity agreement.

Michael Arbige

Dr. Michael V. Arbige, Ph.D., is Independent Director of Solazyme Inc. In May 2011, E.I. du Pont de Nemours and Company acquired Genencor International, Inc., a division of Danisco US Inc., a diversified biotechnology company, and Dr. Arbige was appointed Vice President, Research and Development of DuPont Industrial Biosciences. He is responsible for all activities associated with managing and driving the research and development activities for DuPont Industrial Biosciences. From 1990 to 2011, Dr. Arbige held a variety of positions at Genencor, most recently as its Executive Vice President of Research and Development, a position he held from 2009 to 2011. Dr. Arbige obtained his Ph.D. in Microbial Physiology and Genetics in 1982 from the University of New Hampshire.

Ian Clark

Mr. Ian T. Clark is Independent Director of Solazyme Inc. Mr. Clark currently serves as chief executive officer of Genentech, Inc., a member of the Roche Group, and head of North American Commercial Operations. He was appointed to this role in January 2010. Mr. Clark also leads the Genentech executive committee and is a member of the Genentech board of directors. Mr. Clark joined Genentech in 2003 as senior vice president and general manager, BioOncology. In August 2005 he was named senior vice president, Commercial Operations and became a member of the executive committee, and in January 2006, he was named executive vice president, Commercial Operations. In April 2009, he was named head of Global Product Strategy and chief marketing officer. Prior to joining Genentech, Mr. Clark served as president of Novartis Canada, overseeing all of the company’s country operations. Before assuming his post in Canada, Mr. Clark served as chief operating officer for Novartis United Kingdom. Prior to joining Novartis in 1999, Mr. Clark worked in vice presidential roles in sales and marketing for Sanofi (Aventis) and Ivax in the United Kingdom and Eastern Europe. Mr. Clark has served on the board of the Biotechnology Industry Organization (BIO) Industry Association since 2009, is an advisor to the Institute of Life Sciences at Southampton University in the United Kingdom, and is a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council. Mr. Clark received a Bachelor of Science degree in biological sciences from Southampton University in the United Kingdom.

Basic Compensation

Name Fiscal Year Total

Jerry Fiddler

--

Jonathan Wolfson

3,477,950

Tyler Painter

1,926,360

Peter Licari

1,925,580

Paul Quinlan

1,229,730

James Craigie

--

Peter Kovacs

--

Gary Pfeiffer

--

Michael Arbige

--

Ian Clark

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Jerry Fiddler

0 0

Jonathan Wolfson

106,059 783,564

Tyler Painter

0 0

Peter Licari

66,000 587,578

Paul Quinlan

27,000 216,187

James Craigie

0 0

Peter Kovacs

0 0

Gary Pfeiffer

0 0

Michael Arbige

0 0

Ian Clark

0 0
Search Stocks